Fig. 4: Prophylactic vaccination with CRX-527-peptide conjugates potentiates tumor protection compared to unconjugated vaccines. | npj Vaccines

Fig. 4: Prophylactic vaccination with CRX-527-peptide conjugates potentiates tumor protection compared to unconjugated vaccines.

From: Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control

Fig. 4

a Schematic overview of the experiment. Mice (n = 9) were primed and boosted at an interval of 2 weeks and later challenged with 100,000 B16OVA tumor cells. At the indicated time points, blood was withdrawn to analyze SIINFEKL-specific CD8 responses by tetramer staining. b Frequencies of SIINFEKL-specific CD8 T cell responses in all vaccinated and unvaccinated groups on the day of B16-OVA challenge and 7 days later. c Average B16-OVA tumor growth in groups that were unvaccinated (gray line) or vaccinated with either CRX-527 conjugate (blue line) or a mixture of CRX-527 and peptide (red line) containing OVA CTL or Helper epitopes. Data are displayed as mean ± SD. d Overall survival of prophylactically vaccinated mice with the indicated epitopes in form of CRX-527 conjugates or mixture. Statistical significance was determined by Log-rank Mantel–Cox test; *p < 0.05, **p < 0.01, ***p < 0.001, *****p < 0.0001.

Back to article page